TrustChain Verification · Preliminary Pre-Screening Analysis Confidential · Recipient Use Only
UX Elevation Capital | TrustChain
India–GCC Corridor · Preliminary Pre-Screening Analysis · Pharma AI and HCP Engagement
Assessment Verdict · TC-PV-2026-004
CONDITIONAL Three structural gaps identified. Product traction is exceptional. File requires sovereign framing before GCC introduction.
Preliminary · Based on founder-provided information and public sources · Full evaluation requires Phase 01 engagement
Subject: Peak Velocity · Founder: Mayank Guptaa · India · Assessment scope: India–GCC institutional capital readiness across six categories, 44 markers.
Markers Assessed
44 / 44
Categories
6 of 6
Gaps Identified
3 Structural
Phase 02 Ready
Post-Remediation
Section 01
Assessment Scope & Basis

What this analysis
is based on.

Subject Entity
Peak Velocity
India · AI for pharma HCP engagement and sales rep productivity
Assessment Type
India–GCC Corridor Pre-Investment
Sovereign and family office capital readiness
Analysis Basis
Founder-provided information · Direct assessment call · Public company profile
Full Phase 01 requires pitch deck, cap table, and company documents
Target Capital Channels
SFDA · UAE Ministry of Health · Mubadala Health · M42
Sovereign and family office · GCC pharma and healthcare
Key Traction Signals
Sun Pharma · Cipla · DRL · 20+ pharma companies · Novartis POC · US market entry
GCC Readiness
GCC explicitly on roadmap · Strong institutional references · Sovereign framing gaps present
3
Markers: Pass
2
Gaps: High Priority
1
Critical: Must Resolve
Section 02
Protocol Diagnostics

44-marker scan.
Six categories.

Category Assessment Score
Institutional References
Pass
91%
Product Deployment Depth
Pass
87%
GCC Market Roadmap
Pass
72%
Regulatory Pathway Translation
Gap Identified
38%
GCC Reference Translation
Gap Identified
31%
Exit & Horizon Framing
Critical Gap
18%
Section 03
Verified Strengths

What passed assessment.
Three confirmed signals.

01
Sun Pharma National Scale Deployment
6,000 gynecologists across India. 25,000 patient awareness videos in six weeks. 6 million women reached. This is not a pilot or a POC. This is national healthcare infrastructure deployment at scale. GCC sovereign healthcare programs evaluate on institutional deployment references. A national-scale deployment for one of India's largest pharma companies is exactly the kind of reference that moves a file from the inbound pile to the active review pile at Mubadala Health and M42.
 Verified
02
Multi-Brand Institutional Pharma Track Record
Sun Pharma, Cipla, DRL, and 20+ pharma companies across two distinct product verticals. HCP engagement and sales rep productivity. Both are active deployment areas for GCC pharma digitization mandates. The breadth of validated use cases across different pharma categories and therapeutic areas significantly strengthens the file at sovereign review. Novartis POC adds a global pharma reference that translates directly to GCC institutional credibility.
 Verified
03
GCC Explicitly on Strategic Roadmap
Peak Velocity has explicitly identified GCC as a prime target market with clear rationale. Companies that have already made the strategic decision to enter GCC are significantly easier to position for sovereign pre-screening than companies that need to be convinced the corridor is relevant. The strategic alignment is already there. What is missing is the file framing to make that alignment legible to sovereign reviewers.
 Verified
Section 04
Assessment Findings · Remediation Required

Three structural gaps.
None are product gaps.

Finding PV-001 · High Priority
Regulatory Pathway Translation for SFDA and UAE Ministry of Health
High
Peak Velocity's current positioning reads as a commercial AI SaaS platform serving Indian pharma commercial teams. That framing is appropriate for India market sales conversations. It is the wrong framing for GCC sovereign pre-screening. The Saudi Food and Drug Authority and UAE Ministry of Health have specific compliance requirements for AI-driven HCP engagement platforms operating in their regulated pharma environments. MLR compliance workflows, data sovereignty for patient communication content, regulatory approval pathways for AI-generated medical content. If those regulatory pathway translations are not explicitly documented in the file the platform reads as unvetted commercial technology rather than a regulated healthcare infrastructure deployment. That distinction determines which desk at SFDA and UAE Ministry of Health receives the file.
Resolution · SFDA and UAE MOH regulatory pathway documentation · 5 to 7 business days
Finding PV-002 · High Priority
India Pharma Reference Translation to GCC Market Equivalents
High
Sun Pharma, Cipla, and DRL are major Indian pharma brands. They are not household names at GCC sovereign healthcare desks. The deployment references need to be translated explicitly into GCC pharma market context. This means mapping each Indian pharma brand to their GCC market presence and equivalents. Sun Pharma's UAE and Saudi operations. Cipla's GCC distribution partnerships. DRL's Middle East market footprint. The Novartis POC is actually the strongest single reference in the file for GCC institutional review because Novartis is a globally recognized brand with a direct GCC presence. That reference should be elevated to the front of the file, not buried alongside Indian brand references that require context to evaluate.
Resolution · GCC pharma reference mapping and Novartis elevation · 3 to 5 business days
Finding PV-003 · Critical · Must Resolve Before Phase 02
Exit and Horizon Framing Incompatible with Sovereign Capital
Critical
GCC sovereign healthcare capital and family offices deploy on 10 to 15 year national partnership timelines. Mubadala Health and M42 are building long-term healthcare infrastructure, not managing VC portfolios with 5 to 7 year exit cycles. Any language in Peak Velocity's file that implies a commercial SaaS growth trajectory calibrated for VC exits will trigger a silent rejection at internal sovereign review. This does not mean the company cannot pursue VC capital in parallel. It means the GCC sovereign file needs a completely separate partnership narrative that describes what Peak Velocity looks like as a national pharma AI infrastructure partner across the GCC in 2035 and beyond. The Sun Pharma case study actually provides the perfect framing template. National scale. Regulated deployment. Measurable health outcomes. Long-term infrastructure thinking. That story needs to be the opening frame of the GCC sovereign file.
Resolution · Sovereign partnership narrative and exit horizon reframe · 7 business days
Section 05
Phase 02 · Target Institutions

Four named mandates.
Post-remediation introduction targets.

SFDA
Saudi Arabia
Pharma AI Digitization · Active Mandate
Saudi Food and Drug Authority. Deploying AI-driven pharma digitization infrastructure under Vision 2030 healthcare mandate. HCP engagement compliance and patient communication platforms are a documented deployment priority. Regulatory pathway translation gap must be resolved before introduction.
 Active
UAE MOH
United Arab Emirates
Healthcare AI Infrastructure · Active Mandate
UAE Ministry of Health. Active deployment of AI-driven healthcare digitization infrastructure. Pharma HCP engagement and patient awareness platforms align directly with national healthcare AI deployment programs. Strong data sovereignty requirements favor platforms with regulated compliance workflows.
 Active
Mubadala Health
Abu Dhabi, UAE
Healthcare Infrastructure Investment · Active
Mubadala Investment Company healthcare portfolio. Actively deploying into healthcare AI and digital health infrastructure across the GCC. National scale deployment references like the Sun Pharma case study align directly with Mubadala Health's infrastructure investment thesis. Exit horizon framing gap must be resolved before introduction.
 Active
M42
Abu Dhabi, UAE
AI-Powered Healthcare · Active Deployment
M42 is a joint venture between Mubadala and G42 focused on AI-powered personalized medicine and healthcare infrastructure. HCP engagement AI with national scale deployment track record maps directly to M42's clinical AI infrastructure deployment mandate across the GCC.
 Active
Section 06
Assessment Methodology

How the protocol works.
What makes it rigorous.

44
Total Markers
Every file evaluated against 44 markers across six categories built specifically around GCC sovereign and family office pre-screening criteria.
6
Categories
Ownership and Control · Regulatory Compliance · Vision 2030 Alignment · Commercial Model · Exit and Horizon Framing · Introduction Readiness
3
Possible Verdicts
GO · CONDITIONAL · NO-GO. Each issued with specific resolution paths and named institutional introduction targets for Phase 02.
TrustChain Verification · Performance Commitment · TC-PV-2026-004
If Phase 02 outreach produces no institutional engagement within 30 days of activation, TrustChain Verification will refund the Phase 01 evaluation fee of $2,500 USD in full.
The success fee structure on Phase 02 means TrustChain only generates revenue when Peak Velocity generates capital. Aligned incentives are the foundation of this engagement model.
Section 07
Engagement Structure

Two phases.
One corridor.

Phase 01 · Full Evaluation $2,500 USD · One Time
The Assessment
Full 44-marker forensic protocol applied to Peak Velocity's file. GO, CONDITIONAL, or NO-GO verdict with specific resolution paths. Live dashboard with complete transparency on every marker. Engagement letter via DocuSign. Work begins within 24 hours of payment confirmation.
44-marker full protocol GO · CONDITIONAL · NO-GO verdict Resolution paths for every gap Named GCC institution mapping Live dashboard · Full transparency
Phase 02 · Institutional Introduction 4–6% Success Fee · No Retainer
The Introduction
Named introductions to SFDA, UAE Ministry of Health, Mubadala Health, and M42. Each introduction goes to a specific decision-maker at a specific institution with a confirmed mandate for pharma AI and HCP engagement infrastructure. Activated immediately after Phase 01 gap remediation is complete.
Named introductions only SFDA · UAE MOH · Mubadala Health · M42 Pre-cleared file · Higher internal priority 30-day engagement guarantee
Phase 01 · Full Forensic Evaluation · TC-PV-2026-004
$2,500
One-time fee · 7 to 10 business days · 30-day refund guarantee
Peak Velocity already has the traction. Sun Pharma at national scale. Novartis POC in the US. The work is not building the product. The work is framing it correctly for GCC sovereign review. That is what the $2,500 evaluation delivers.
✓ Full 44-marker forensic protocol across six GCC sovereign pre-screening categories
✓ GO, CONDITIONAL, or NO-GO verdict with specific resolution paths for every identified gap
✓ Named GCC institution mapping — SFDA, UAE Ministry of Health, Mubadala Health, M42 with documented mandate alignment
✓ Live dashboard with real-time transparency on every marker and resolution step throughout the evaluation
✓ Phase 02 activation — named introductions to SFDA, UAE MOH, Mubadala Health, M42 on 4 to 6% success fee only
✓ 30-day performance guarantee — full $2,500 refund if Phase 02 produces no institutional engagement
Request Engagement Letter · Begin Phase 01 →
Engagement letter issued via DocuSign · Payment via Stripe · Work begins within 24 hours
IMPORTANT DISCLOSURE: This preliminary pre-screening analysis (TC-PV-2026-004) was prepared by TrustChain Verification, operating under UX Elevation Capital (Delaware C-Corp), for the exclusive use of Peak Velocity and its authorized representatives. This analysis is based on founder-provided information and publicly available sources. It does not constitute investment advice, a guarantee of capital deployment, or a representation of institutional commitment from any named GCC institution. The full Phase 01 evaluation requires submission of pitch deck, cap table, company registration documents, and supporting materials. TrustChain Verification is a forensic verification and pre-investment assessment platform. The 30-day engagement guarantee applies exclusively to Phase 02 introduction outreach and is subject to the terms of the executed engagement letter.